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Highly active antiretroviral therapy (HAART)-associated metabolic complications include lipoatrophy (loss of subcutaneous
adipose tissue(SAT)) and insulinresistance. Thiazolidinediones are insulin-sensitizingantidiabetic agents which—as an untoward
side eﬀect in obese diabetic patients—increase SAT. Furthermore, troglitazone has improved lipoatrophy and glycemic control
in non-HIV patients with various forms of lipodystrophy. These data have led to 14 clinical trials to examine whether
thiazolidinediones could be useful in the treatment of HAART-associated metabolic complications. The results of these studies
indicate very modest, if any, eﬀect on lipoatrophic SAT, probably due to ongoing HAART negating the beneﬁcial eﬀect. The
beneﬁt might be more prominent in patients not taking thymidine analoges. Despite the poor eﬀect on lipoatrophy, thiazolidin-
ediones improved insulin sensitivity. However, especially rosiglitazone induced harmful eﬀects on blood lipids. Current data
do not provide evidence for the use of thiazolidinediones in the treatment of HAART-associated lipoatrophy, but treatment of
lipoatrophy-associated diabetes may be warranted. The role of thiazolidinediones for novel indications, such as hepatosteatosis,
should be studied in these patients.
Copyright © 2009 Jussi Sutinen.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The prognosis of HIV-infection has drastically changed
after the introduction of combination antiretroviral therapy
[1] often referred to as highly active antiretroviral therapy
(HAART). Since the eradication of the virus is impossible
withcurrentmedicines[2]andsinceperiodictreatmentwith
HAART can be harmful when compared to continuous ther-
apy [3], patients need to continue therapy uninterruptedly
and permanently.
Lifelong exposure to HAART puts patients at a signif-
icant risk for long-term metabolic adverse eﬀects includ-
ing lipodystrophy, insulin resistance, hyperlipidemia, and
increased cardiovascular morbidity [4, 5]. The most char-
acteristic component of HAART-associated lipodystrophy is
the loss of subcutaneous adipose tissue [6] which has proven
to be very diﬃcult to treat (Figure 1).
Thiazolidinediones (glitazones) are oral insulin-sensiti-
zing antidiabetic agents. As an untoward side eﬀect, gli-
tazones increase subcutaneous fat mass in patients with
type 2 diabetes [7–9]. Additionally, in non-HIV infected
patients with various forms of lipodystrophy, troglitazone
has improved metabolic control and subcutaneous lipoatro-
phy [10]. These insulin-sensitizing and fat-inducing eﬀects
of glitazones have lead to several clinical trials examining
whether these drugs could reverse lipoatrophy and insulin
resistance in patients with HAART-associated lipodystrophy.
The ensuing review is focused on summarizing the
currently available clinical data on the use of glitazones in
patients with HAART-associated lipodystrophy
2.Thiazolidinediones
Thiazolidinediones are synthetic ligands for peroxisome
proliferator-activated receptor gamma (PPARγ). PPARγ is a
nuclear receptor which alters expression of multiple genes
including those regulating lipid and glucose metabolism
[11]. PPARγ is expressed mainly in adipose tissue and is
also found in pancreatic beta cells, vascular endothelium,
and macrophages, and in low quantities in other tissues such2 PPAR Research
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Figure 1: Abdominal magnetic resonance image (MRI) of a
HAART-treated patient with normal fat distribution (a) and a
patientwithsevereHAART-associatedlipodystrophywithcomplete
loss of subcutaneous fat and accumulation of intra-abdominal fat
(b). Fat is shown white in these MRI images.
as the liver, skeletal muscle, and the heart [12, 13]. The
activation of PPARγ is critical in adipocyte diﬀerentiation,
fatty acid uptake, and storage in the adipocytes [14, 15].
Glitazone-induced activation of PPARγ in adipose tissue
may improve the whole body insulin sensitivity by keeping
fatty acids within adipocytes and hence protecting other
tissues (liver, skeletal muscle, and pancreatic beta cells) from
the “toxic” eﬀects of the high-circulating concentration of
free fatty acids [12]. Alternatively or additionally, glita-
zones may aﬀect whole body insulin sensitivity by altering
adipokine release from adipose tissue [12].
The potential role of PPARγ in the pathogenesis of some
human lipodystrophies has been demonstrated in recent
studies ﬁnding dominant negative and loss-of-function
mutations to aﬀect the ligand-binding domain of PPARγ
in non-HIV patients with partial lipodystrophy, hepatic
steatosis, dyslipidemia, and insulin resistance [13]. Further-
more, trogilitazone was shown to improve subcutaneous
lipoatrophy in HIV-negative patients with various forms of
lipodystrophic/lipoatrophic syndromes [10]. Taken together,
the available data make glitazones an interesting therapy
option for HAART-associated lipodystrophy.
3.HAART-AssociatedLipodystrophy
The prevalence of HAART-associated lipodystrophy has
varied from as low as 2% [16] up to 83% [17] in HAART-
treated patients. This huge variation is explained by the lack
of uniformly accepted deﬁnition of lipodystrophy, and the
variable combination and duration of HAART in diﬀerent
studies. Estimates from large surveys indicate a prevalence
of 50% of at least one physical abnormality after 12–18
months of therapy [18, 19]. Most of these prevalence data
arise from patients taking mainly the older and metabolically
more toxic antiretroviral regimens. Although there are
accumulating data demonstrating a signiﬁcantly decreased
risk for lipodystrophy in patients taking newer antiretroviral
agents [20, 21], lipodystrophy still remains a signiﬁcant
clinical problem.
Lipoatrophy, that is, a decrease in subcutaneous adipose
tissue (SAT) mass, has mainly been attributed to the use
of nucleoside reverse transcriptase inhibitors (NRTIs) and
thymidine analoges (tNRTI) in particular [22–25]. The
tNRTIs stavudine and more recently zidovudine gradually
decrease SAT mass. Typically, SAT initially increases during
the ﬁrst 4–8 months of therapy, but thereafter, a 19%
decrease in limb fat per year has been described with
stavudine and didanosine containing regimens as compared
to a decrease of 1.7% per year with zidovudine and lamivu-
dine [26]. Further evidence demonstrating the deleterious
eﬀects of tNRTIs on SAT arises from the so called “switch”
studies. Replacing tNRTI by abacavir or tenofovir has in
several studies lead to an increase of 300–500g of limb
fat during the ﬁrst 6–12 months after the switch [27–29].
Although most data indicate a major role of tNRTIs in
the development of lipoatrophy, other drug classes may
be involved. Irrespective of the NRTI backbone, nelﬁnavir
(a protease inhibitor) was associated with more severe
fat loss than efavirenz (nonnucleoside reverse transcriptase
inhibitor) [30], whereas in another study efavirenz caused
more fat loss than lopinavir/ritonavir (protease inhibitor)
[31]. The less signiﬁcant role of protease inhibitors (PIs) for
lipoatrophyisdemonstratedintheswitchstudies.Incontrast
to the beneﬁcial eﬀects of switching away from tNRTIs, the
eﬀects of switching away from PIs have been disappointing
regarding lipoatrophy [32].
The potential pathophysiological mechanisms leading
to lipoatrophy include NRTI-induced inhibition of mito-
chondrial (mt) DNA polymerase gamma through several
diﬀerent mechanisms [33, 34]. This inhibition would lead to
decreased mtDNA content which consequently would result
in depletion of proteins encoded by mtDNA and dysfunc-
tional mitochondria. Additionally, also genes encoded by
nuclearDNAareaﬀectedbyNRTIs,andthesedrugspromote
apoptosis in adipocyte cell modes in vitro [35].
In keeping with these in vitro data, human studies
have shown decreased mtDNA content in adipose tissue
of patients with HAART-associated lipodystrophy when
compared to HIV-negative subjects, HIV-infected patients
not taking HAART, or to HAART-treated patients without
lipodystrophy [36–39]. However, studies in healthy subjects
have shown that a 2-week exposure to NRTIs leads to a
decrease in mtRNA and alters expression of several nuclear
genes without a signiﬁcant change in the mtDNA content
[40]. Various studies have shown multiple alterations in gene
expression in lipoatrophic adipose tissue such as decreased
expression of several transcription factors (PPARγ,S R E B P -
1c (sterol regulatory element-binding protein), PPARδ,PPAR Research 3
C/EBPα,a n dβ (CCAAT/enhancer-binding protein)) [41,
42]. Alterations have also been described in the expression of
several genes involved in lipogenesis, fatty acid, and glucose
metabolism, for example, the expressions of acyl coenzyme
A synthase, lipoprotein lipase, and glucose transport pro-
tein 4 are decreased in patients with HAART-associated
lipodystrophy [42]. Several markers of inﬂammation such
as interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα),
CD45, and CD68 have been shown to be increased in
lipoatrophic adipose tissue [41–44]. Of the adipokines, the
expressionofadiponectininadiposetissueanditscirculating
concentration have been shown to be decreased in several
studies[44–47],whereasserumconcentrationsofleptinhave
been either decreased [48, 49], unchanged [46, 50, 51],
or increased [52] in lipoatrophic patients. In addition to
these ﬁndings implying severe adipose tissue dysfunction,
increasedrateofapoptosishasalsobeendescribedintheSAT
of these patients [43, 53].
Although multiple alterations have been described in
lipoatrophic adipose tissue, the role and sequence of each
critical abnormality eventually leading to loss of SAT still
remain elusive. It also remains unknown which critical
abnormalities should be counteracted in order to reverse
HAART-associated abnormalities in adipose tissue of these
patients, and whether thiazolidinediones would have this
potential.
4. Thiazolidinediones for HAART-Induced
MetabolicAdverse Effects
Thiazolidinediones have been used in 14 clinical trials in
HIV-infected, HAART-treated patients [54–67]. The basic
characteristicsofthesetrialsaregivenin Table 1.Intotal,281
patients have used rosiglitazone, 82 patients pioglitazone,
and 6 patients troglitazone in these trials. Four of these trials
were open label-uncontrolled studies [54, 59, 64, 67], 6 were
randomized placebo-controlled studies [55–57, 61, 62, 66],
and 4 had a comparison arm with another active agent
(metformin or fenoﬁbrate) [58, 60, 63, 65]. Followup times
varied from 6 weeks to 12 months.
The presence of lipoatrophy without reference to insulin
resistance was the inclusion criteria in ﬁve studies [55, 56,
58, 64, 66], one additional study required the presence of
at least one feature of lipodystrophy (but not necessarily
lipoatrophy) without reference to insulin resistance [62].
Insulin resistance (deﬁned by fasting insulin concentration,
oral glucose tolerance test, or clamp studies) without ref-
erence to lipodystrophy was the inclusion criteria in three
studies [54, 63, 65]. One study required the presence of
both lipoatrophy and insulin resistance [57], and another
study included patients with changes in body fat (but not
necessarilylipoatrophy)togetherwithinsulinresistance[60].
The troglitazone study included patients with newly diag-
nosed diabetes with lipodystrophy and dyslipidemia [67],
and two studies did not specify any metabolic abnormalities
in the inclusion criteria [59, 61]. The exclusion criteria
were variable, but often included liver function tests >2-3
times upper limit of normal, serum creatinine >1-2 times
upper limit of normal, haemoglobin <90–95g/L, serum
triglycerides >10–15mmol/L, presence of heart failure, and
pregnancy.
4.1. Eﬀects on Body Composition. Body composition data
from the eight studies which included a control arm and an
objective measurement of subcutaneous fat (dual-energy X-
ray absorptiometry [DEXA], computed tomography [CT],
magnetic resonance imaging [MRI]) are included in Table 2.
No signiﬁcant changes in the amount of subcutaneous fat
could be detected in four studies: two of these studies used
a single method to measure adipose tissue volume (one with
MRI [55], one with DEXA [62]), and the other two studies
measured fat volume using both DEXA and CT [56, 65]. In
contrast to these four studies, three other studies reported
statistically signiﬁcant increases in SAT in patients taking
eitherrosiglitazone[57,60]orpioglitazone[66]ascompared
toplacebo.SATwasquantiﬁedbybothDEXAandCTscanin
all these three studies, but none of the studies could conﬁrm
the statistically signiﬁcant increase in SAT versus placebo
by the second method in the same study. The absolute
changes in SAT in the thiazolidinedione arm were reported
in two studies: an increase of 50g in leg fat mass after 12-
week treatment with rosiglitazone [57], and 380g increase
in limb fat mass in the pioglitazone arm after 48 weeks of
therapy [66]. In the study by van Wijk et al. rosiglitazone
was compared to metformin without a placebo arm [58].
In this study, there was a statistically signiﬁcant increase in
SAT measured by CT scan in the rosiglitazone arm versus
baseline, and also relative to metformin. DEXA scanning was
not performed in this study.
Onestudyfoundastatisticallyalmostsigniﬁcantincrease
in visceral adipose tissue (VAT) in the rosiglitazone group
when compared to placebo [60], while there were no
signiﬁcantchangesinVATbetweentheglitazoneandplacebo
arms in the other studies. None of the placebo-controlled
trials reported signiﬁcant changes in BMI either within the
glitazone arm or between the placebo and glitazone group,
although the diﬀerence approached statistical signiﬁcance
in the pioglitazone trial by Slama et al. [66]. In the
study comparing rosiglitazone and metformin, there was a
signiﬁcant increase in body mass index (BMI) within the
rosiglitazonearmfrombaseline,andalsothechangebetween
the rosiglitazone and metformin arm was statistically sig-
niﬁcant [58]. The studies ﬁnding no signiﬁcant increase
in SAT reported changes in body weight ranging from a
loss of 3.0kg to the gain of 3.8kg in the thiazolidine arm
[55, 56, 62, 65]. In contrast to variable eﬀects seen on body
weight with glitazones, all three studies having a metformin
arm [58, 60, 63] reported a decrease in body weight from 1.2
to 2.2kg in patients using metformin.
The eﬀects of thiazolidinediones on body composition
in HAART-treated patients contrast data from HIV-negative
diabetic patients. In these patients, thiazolidinediones have
increasedbodyweightconstantlyby2–4kgafter16–26weeks
of therapy [12]. This increase has been attributed mainly to
an increase in the fat mass and in some patients to edema
[12]. The increase in total fat mass has been in the order of
1.5–4kgafter3-4monthsofrosiglitazonetherapy[9,68,69],4 PPAR Research
Table 1: The basic characteristics of the studies with thiazolidinediones in HIV-infected, HAART-treated patients. HAART = highly active
antiretroviral therapy, IR = insulin resistance, LA = lipoatrophy, OGTT = oral glucose tolerance test, LD = lipodystrophy.
Number of
subjects
Study design Study groups Duration Inclusion criteria Reference
Rosiglitazone studies
8 Open label, uncontrolled Rosiglitazone 8mg/d 6–12 weeks IR (deﬁned by clamp) Gelato et al. [54]
30
Randomized, double
blind
Rosiglitazone8mg/d,
or placebo 24 weeks LA (clinical deﬁnition) Sutinen et al. [55]
108
Randomized, double
blind
Rosiglitazone8mg/d,
or placebo 48 weeks LA (limb fat% <20%, or limb fat%
at least 10% less than truncal fat%) Carr et al. [56]
28
Randomized, double
blind
Rosiglitazone
4mg/d, or placebo 3m o n t h s
LA (clinical deﬁnition) and IR (fas-
ting insulin >15μIU/ml, or 2h ins-
ulin [OGTT] >75μIU/ml)
Hadigan et al. [57]
39 Randomized, open label Rosiglitazone8mg/d,
or metformin 2g/d 26 weeks LA (clinical deﬁnition) van Wijk et al. [58]
20 Open label, uncontrolled Rosiglitazone 4mg/d 24 weeks No LD or IR requirements Feldt et al. [59]
105
Randomized, double
blind
Rosiglitazone4mg/d,
or metformin 2 g/d,
orrosiglitazone+me-
tformin, or placebo
16 weeks
IR (fasting insulin >15μIU/ml, or
2h insulin [OGTT] >75μIU/ml, or
2h glucose [OGTT] >7.7mmol/L
andfastinginsulin>10μIU/ml)and
self-reported changes in body fat
(including increased waist-to-hip
ratio or waist circumference)
Mulligan et al. [60]
37
Randomized, double
blind
Rosiglitazone8mg/d,
or placebo 6m o n t h s Body mass index 19–24kg/m2,n o
requirements on LD or IR Haider et al. [61]
96
Randomized, double
blind
Rosiglitazone4mg/d,
or placebo 24 weeks LD (clinical deﬁnition) Cavalcanti et al. [62]
90 Randomized, open label
Rosiglitazone4mg/d,
or metformin 1g/d,
or no treatment
48 weeks
IR (impaired fasting glucose or im-
paired glucose tolerance [OGTT],
with fasting insulin >20μIU/ml)
Siliˇ ce ta l .[ 63]
Pioglitazone studies
11 Open label, uncontrolled Pioglitazone 45 mg/d 6 months LA (clinical deﬁnition) Calmy et al. [64]
14
Randomized, double
blind (2 ×2f a c t o r i a l )
Pioglitazone 30–45
mg/d, or fenoﬁbrate
200mg/d, or pioglit-
azone + fenoﬁbrate,
or placebo
12 months
IR (impaired glucose tolerance
[OGTT], or diabetes, or fasting ins-
ulin >20μIU/ml) and dyslipidemia
Gavrila et al. [65]
130
Randomized, double
blind
Pioglitazone
30mg/d, or placebo 48 weeks LA (clinical deﬁnition) Slama et al. [66]
Troglitazone study
6 Open label, uncontrolled Troglitazone
400mg/d 3 months LD and newly diagnosed diabetes Walli et al. [67]
and it consists almost exclusively of the increase in the
subcutaneous fat depot [7, 8, 69, 70]. Similar eﬀects on body
fat have also been described in nondiabetic patients treated
with pioglitazone for insulin resistance [71] or nonalcoholic
steatohepatitis [72].
Table 3 lists some confounding factors that possibly
could explain the conﬂicting results of thiazolidinediones on
SAT in diﬀerent trials with HIV-infected, HAART-treated
patients. The drug dose, study duration, inclusion criteria
and baseline BMI appeared to be similar between studies
showing a statistically signiﬁcant increase versus those not
showing a change in SAT. The prevalence of concomitant
use of stavudine, the NRTI most strongly associated with
fat loss, may explain some of the discrepancies, since the
studies reporting an increase in SAT were those with least
frequent use of stavudine [57, 58, 66]. Also in the study by
Carr et al., after 24 weeks of treatment with rosiglitazone,
there was a statistically almost signiﬁcant increase in SAT
in those patients not taking stavudine or zidovudine when
compared to the placebo group (+480g versus 190g, P =
.06), but this diﬀerence was not maintained at week 48 [56].
Similarly, in the study by Slama et al., patients not taking
stavudine at baseline had a mean increase of limb fat mass
of 450g in the pioglitazone group versus 40g increase in the
placebo group (P = .013) [66]. Based on these data one can
hypothesize that thiazolidinediones may have a fat-inducingPPAR Research 5
Table 2: Body composition data from thiazolidinedione studies which included a control arm and an objective measurement of body
composition in HIV-infected, HAART-treated patients. HAART = highly active antiretroviral therapy, SAT = subcutaneous adipose tissue,
NS = nonsigniﬁcant, MRI = magnetic resonance imaging, DEXA = dual-energy X-ray absorptiometry, CT = computed tomography, s.c. =
subcutaneous, ND = not done, CI = conﬁdence interval.
N Drug Duration Subcutaneous adipose
tissue Visceral adipose tissue Body mass index
(kg/m2) Reference
No change
in SAT 30 Rosi versus
placebo 24 weeks MRI: NS MRI: NS NS Sutinen et al. [55]
108 Rosi versus
placebo 48 weeks
DEXA limb fat: NS
CT thigh: NS
CT s.c. abdomen: NS
CT: NS NS Carr et al. [56]
14
Pio versus
feno
versus pio
+f e n o
versus
placebo
12 months
DEXA upper limb fat: NS
DEXA lower limb fat: NS
CT s.c. abdomen: NS
CT: NS NS Gavrila et al. [65]
96 Rosi versus
placebo 24 weeks
DEXA limb fat: NS DEXA
arm fat: NS DEXA leg fat:
NS
ND NS Cavalcanti et al. [62]
Increase
in SAT 28 Rosi versus
placebo 3m o n t h s
CT thigh (cm2): rosi: + 2.3
versus pla −0.9, Δ rosi
versus pla, P = .002 CT s.c.
abdomen: NS DEXA leg:
NS (rosi +50g versus pla
−80g, Δ rosi versus pla
P = .08)
CT: NS NS Hadigan et al. [57]
105
Rosi versus
metformin
versus rosi
+m e t
versus
placebo
16 weeks
DEXA leg fat (%): rosi:
+4.8, ∗NS; met: −3.6, ∗NS;
rosi + met: −0.5, ∗NS; pla:
−8.3%, ∗NS Δ rosi vs pla
P = .03, other groups
versus pla, NS DEXA arm
fat: NS DEXA limb fat: NS
CT s.c. abdomen: NS
CT (%): rosi: 0.0, ∗NS;
met: −0.6,∗NS; rosi +
met: −7.9, ∗NS; pla:
−7.2, ∗NS Δ rosi
versus pla, P = .08,
other groups versus
pla, NS
Body mass index ND,
body weight (kg): rosi:
0.0, ∗NS; met: −2.0,
∗P<. 001; rosi + met:
−1.5, ∗P<. 01; pla:
−0.05, ∗NS Δ met
versus pla, P = .03; Δ
met + rosi versus pla,
P = .06
Mulligan et al. [60]
130 Pio versus
placebo 48 weeks
DEXA limb fat (g): pio:
+380g; pla: +50g Δ pio
versus pla P = .051 CT s.c.
abdomen: NS
CT: NS Pio: +0.9; pla: +0.3 Δ
pio versus pla P = .07 Slama et al. [66]
39 Rosi versus
metformin 26 weeks
CT s.c. abdomen (cm2)
rosi: +16, ∗P<. 05; met:
−11, ∗P<. 05 Δ rosi versus
met 27cm2 (95% CI, 7 to
46)
CT (cm2)r o s i :−1,
∗NS; met: −25,
∗P<. 05 Δ rosi versus
met 24 cm2 (95% CI, 6
to 51)
Rosi: +0.4, ∗P<. 05;
met: −0.4, ∗P<. 05 Δ
rosi versus met 0.7
(95% CI, 0.5 to 1.6)
van Wijk et al. [58]
∗ denotes signiﬁcance within the study group compared to baseline value, Δ denotes comparison of the change between respective study groups.
eﬀect in lipoatrophic SAT, but the ongoing stavudine (and
zidovudine) treatment may negate this beneﬁcial eﬀect.
In addition to quantifying adipose tissue compartments,
liver fat content was measured in one study [55]. Liver
fat decreased with rosiglitazone and increased with placebo
(−2.1% versus +2.1% in the rosiglitazone versus placebo,
P<. 05) [55]. Serum alanine aminotransferase (ALT)
concentrations were reported in 5 rosiglitazone studies [55–
58, 60]. In three of these studies, there was a statistically
signiﬁcantdecreaseinALTconcentrationintherosiglitazone
arm compared either to the baseline value or to the placebo
armpossiblysuggestingadecreaseinliverfatcontent[55,56,
58].
Outside these trials, a single case report describes
development of several dozen lipomas in a patient with
HAART-associated lipoatrophy during 3-month therapy
with rosiglitazone. After rosiglitazone was discontinued, all
but 5 lipomas resolved completely [73].
4.2. Eﬀects on Insulin Resistance and Blood Lipids. The
eﬀects of thiazolidinediones on glycemic indeces in the ten
comparative studies reporting data on glucose and insulin6 PPAR Research
Table 3: Comparison of the baseline characteristics of the thiazolidinedione arms of the studies showing versus not showing an increase in
subcutaneous fat mass in HIV-infected HAART-treated patients. HAART = highly active antiretroviral therapy, SAT = subcutaneous adipose
tissue, NR = not reported.
Drug (dose/d) Duration Inclusion criteria BMI (kg/m2) % taking stavudine Reference
No
change in
SAT
Rosi 8mg 24 weeks Lipoatrophy 24 67 Sutinen et al. [55]
Rosi 8mg 48 weeks Lipoatrophy 23 49 Carr et al. [56]
Pio 30–45mg 12 months Insulin resistance and
dyslipidemia
26 NR Gavrila et al. [65]
Rosi 4mg 24 weeks Lipodystrophy 25 NR Cavalcanti et al. [62]
Increase
in SAT
Rosi 4mg 3 months Lipoatrophy and insulin
resistance
26 44 Hadigan et al. [57]
Rosi 4mg 16 weeks Lipodystrophy and insulin
resistance
Body weight 80kg NR Mulligan et al. [60]
Pio 30mg 48 weeks Lipoatrophy 22 25 Slama et al. [66]
Rosi 8mg 26 weeks Lipoatrophy 24 21 van Wijk et al. [58]
are shown in Table 4. In contrast to the very modest eﬀects
on SAT described above, eight [55–58, 60, 61, 63, 65]o u t
of 10 studies showed improvements in insulin resistance in
the thiazolidinedione arm when compared to the baseline
value or to the placebo arm. One study reported a signiﬁcant
positive correlation between the change in fasting insulin
concentration and the change in liver fat content [55].
Only two studies did not show signiﬁcant improvements in
insulin sensitivity [62, 66]. Of note, insulin resistance was an
inclusion criteria in only four [57, 60, 63, 65] out of these 10
studies.
Since none of the comparative studies recruited patients
with type 2 diabetes, it is diﬃcult to compare these eﬀects
on glycemic indeces in HAART-treated patients to those
in HIV-negative diabetic patients treated with glitazones.
The average decrease in haemoglobin A1c has been 1–1.5%
in non-HIV patients with type 2 diabetes treated with
glitazones [12].
The eﬀects of thiazolidinediones on blood lipids in the
nine comparative studies reporting data on cholesterol and
triglycerides are shown in Table 5.F i v e[ 55–58, 60]o u t
of seven studies with rosiglitazone reported a statistically
signiﬁcant increase in total cholesterol concentration in the
rosiglitazonearmwhencomparedeithertothebaselinevalue
or to the comparative arm. The absolute increases in total
cholesterol concentration in the rosiglitazone arms varied
from 0.4 to 1.4mmol/L. Neither of the two pioglitazone
studies reported signiﬁcant changes in total cholesterol
concentrations [65, 66]. HDL (high-density lipoprotein)
cholesterol concentration increased statistically signiﬁcantly
in both studies with pioglitazone (increases of 0.09 and
0.15mmol/L) [65, 66], but decreased signiﬁcantly in two out
of the seven rosiglitazone studies with absolute decreases of
0.1 and 0.15mmol/L [58, 60]. LDL (low-density lipoprotein)
cholesterolwasmeasuredinﬁverosiglitazonestudies[56–58,
60, 62]. Four of these studies reported signiﬁcant increases in
LDL cholesterol concentrations when compared to the base-
line value (absolute increases between 0.2–0.8mmol/L) or to
thecomparativearm[56–58,60].Theincreaseof1.7mmol/L
in LDL cholesterol was statistically almost signiﬁcant in one
of the two pioglitazone studies [65]. Statistically signiﬁcant
increases in triglyceride concentrations were reported in
three out of seven rosiglitazone studies (versus baseline or
versus the comparative arm) [55, 56, 58]. The absolute
increases were between 0.5–3.0mmol/l. There were no
signiﬁcant changes in triglyceride concentrations in the two
pioglitazone studies. A proatherogenic eﬀect of rosiglitazone
on blood lipids was further described by Hadigan et al.
[74]. Rosiglitazone treatment increased signiﬁcantly the
concentration of small dense LDL cholesterol, and decreased
the concentration of large HDL cholesterol and also of HDL
particle size [74]. In contrast, pioglitazone treatment was
associated with an increase in the LDL particle size (from
19.9 at baseline to 20.6nm at 12 months, P = .06) [65].
The results of these studies with HAART-treated patients
suggest pioglitazone to have a more favorable lipid proﬁle
than rosiglitazone as has been observed in patients with
type 2 diabetes [12]. A striking diﬀerence in HAART-
treated patients relative to HIV-negative diabetic patients
was the signiﬁcant increase in triglyceride concentration by
1.5 to 2.3mmol/L in the rosiglitazone arm in some studies
[55, 56]. One may hypothesize that the increases in serum
triglycerides were possibly aggravated by the high prevalence
of stavudine use in these studies. The ongoing stavudine
treatment may have prevented the storage of circulating
lipids within the adipocytes. In the study by Sutinen et al.,
one patient had to discontinue rosiglitazone treatment due
to serum triglyceride increase up to 32.5mmol/L [55]a n d
anotherpatientusingrosiglitazoneinthestudybyCavalcanti
et al. discontinued due to abnormal lipid values [62]. Carr et
al.reportedgrade3-4increasesintriglycerideconcentrations
in 57% of the participants in the rosiglitazone arm compared
to36%intheplaceboarm[56].ThelargestudybyCavalcanti
et al. did not report any deleterious eﬀects on blood lipid
concentrations by rosiglitazone, but in the same study 15%
of patients in the rosiglitazone arm started lipid-loweringPPAR Research 7
Table 4: The eﬀects of thiazolidinediones on glycemic indeces in controlled trials with HIV infected, HAART-treated patients. HAART =
highly active antiretroviral therapy, HOMA = homeostasis model assessment (fasting insulin [μIU/ml] × fasting glucose [mmol/L]/22.5),
OGTT = oral glucose tolerance test, NS = nonsigniﬁcant, NR = not reported, AUC = area under the curve.
N Drug Duration Insulin (μIU/ml) HOMA OGTT Fasting glucose
(mmol/L) Reference
30 Rosi versus
placebo 24weeks
Rosi: −3.3,
∗P<. 05; pla: +6.7,
∗NS Δ rosi versus
pla P<. 05
NR NR NS Sutinen et al. [55]
108 Rosi versus
placebo 48weeks
Rosi: −3.5; pla:
+0.7 Δ rosi versus
pla P = .02
Rosi: −1.0; pla:
+0.04 Δ rosi versus
pla P = .03
2hg l u c o s e :N S2h
insulin: rosi −13.6;
pla +3.9 Δ rosi
versus pla P = .09
NS Carr et al. [56]
14
Pio versus
feno
versus pio
+f e n o
versus
placebo
12months NS
Pio: −3.8,
∗P<. 05; pla: −1.3,
∗NS
NR NS Gavrila et al. [65]
96 Rosi versus
placebo 2 4 w e e k s N SN SN SN S Cavalcanti et al.
[62]
28 Rosi versus
placebo 3months NS NR
2 h glucose: rosi:
−0.3; pla: +0.1 Δ
rosi versus pla
P = .06 2h insulin
AUC: rosi: −2.3;
pla: +1.8 Δ rosi
versus pla P = .003
NS Hadigan et al.
[57]
105
Rosi versus
metformin
versus rosi
+m e t
versus
placebo
16weeks Rosi: −4, ∗P = .08;
met: −2, ∗P = .07 NR
Insulin AUC: rosi:
−26, ∗P = .012;
met: −11,
∗P = .06; rosi +
met: −18,
∗P = .002 Δ rosi +
met versus placebo
P = .03; Δ rosi
versus pla P = .07
NS Mulligan et al.
[60]
130 Pio versus
placebo 4 8 w e e k s N SN SN SN S S l a m a e t a l . [ 66]
37 Rosi versus
placebo 6months NS
Rosi: −0.1, ∗NS;
pla: +1.3, ∗P<. 05
At 6 months: rosi
versus pla P<. 05
NR NS Haider et al. [61]
90
Rosi versus
metformin
versus No-
treatment
48weeks
Rosi: −19.3,
∗P<. 001; met:
−11.1, ∗P<. 001;
No-Tx: +0.7, ∗NS
At 48 weeks: rosi
versus No-Tx
P<. 001; met
versus No-Tx
P<. 001; met
versus rosi P<. 001
Rosi: −7.3,
∗P<. 001; met:
−6.2, ∗P<. 001;
No-Tx: +0.3, ∗NS
At 48 weeks: rosi
versus No-Tx
P<. 001; met
versus No-Tx
P<. 001; rosi
versus met
P<. 001
NR
Rosi: −1.9,
∗P<. 001; met:
−2.2, ∗P<. 001;
No-Tx: 0.0, ∗NS At
48 weeks: Rosi
versus No-Tx
P<. 001; met
versus No-Tx
P<. 001; rosi
versus met
P = .015
Siliˇ ce ta l .[ 63]8 PPAR Research
Table 4: Continued.
N Drug Duration Insulin (μIU/ml) HOMA OGTT Fasting glucose
(mmol/L) Reference
39 Rosi versus
metformin 26 NR NR
Glucose AUC: rosi:
−1.9, ∗P = .04;
met: −1.1,
∗P = .05 Δ rosi
versus met NS
Insulin AUC: rosi:
−37, ∗P = .01; met
−33, ∗P = .01 Δ
rosi versus met NS
NR van Wijk et al.
[58]
∗ denotes signiﬁcance within the study group compared to baseline value, Δ denotes comparison of the change between respective study groups.
therapy during the study compared to 5% in the placebo
arm [62]. In addition to these prospective clinical trials,
a small retrospective study reported eﬀects of fenoﬁbrate
alone versus fenoﬁbrate in combination with rosiglitazone
in HIV-infected patients [75]. When fenoﬁbrate was given
alone, triglyceride concentrations decreased by 27% and
HDL cholesterol increased by 19%. In contrast, when
fenoﬁbrate was combined with rosiglitazone, triglycerides
increased by 48% and HDL cholesterol decreased by 33%
[75].
Three of the rosiglitazone studies [57, 60, 76] also
reported the eﬀects of rosiglitazone on free fatty acid
(FFA) concentrations. In two of these studies, a statistically
signiﬁcant decrease in FFA concentration was found in the
rosiglitazone arm when compared to baseline value or to
placebo [57, 76].
Serum adiponectin concentration was measured in six
rosiglitazone studies [56–58, 60, 61, 76]. All these studies
showed a statistically signiﬁcant increase of 0.8–4.1μg/ml
in the rosiglitazone arms. One study found an inverse
correlationbetweenthechangeinadiponectinconcentration
and the change in fasting insulin concentration and liver fat
content [76].
Additional ﬁndings from these clinical trials with
HAART-treated patients include either a decline [77]o r
no change [55, 78]i nl e p t i nc o n c e n t r a t i o nw i t hr o s i g l i t a -
zone. Circulating concentrations of inﬂammatory markers
(TNFα, C-reactive protein, or IL-6) did not change in
any study reporting these measurements [78–80]. Plasma
concentrations of PAI-1 (plasminogen activator inhibitor-
1 )a n dt P A( t i s s u ep l a s m i n o g e na c t i v a t o r )w e r er e p o r t e dt o
either decline [79] or remain unchanged [78] with rosiglita-
zone therapy. Plasma resistin concentration decreased with
rosiglitazone in one study [78]. Rosiglitazone decreased
systolic blood pressure, but had a nonsigniﬁcant eﬀect on
ﬂow-mediatedarterialdilatationcomparedtoplaceboinone
study [77].
4.3. Thiazolidinedione-Induced Gene Expression in SAT in
HAART-Treated Patients. Two studies have evaluated the
eﬀectsofrosiglitazoneongeneexpressioninSATinHAART-
treated patients [76, 81]. Sutinen et al. reported statistically
signiﬁcant increases in the expression of adiponectin and
PPARγ coactivator 1 (PGC-1), and a decrease in IL-6
expression with rosiglitazone treatment [76]. In addition,
there was a signiﬁcant increase in PPARγ expression in the
rosiglitazone arm relative to the placebo arm [76]. Mallon
et al. studied gene expression in SAT two and 48 weeks after
rosiglitazone or placebo treatment, and compared patients
taking tNRTIs at baseline to those without tNRTI treatment
[81].Aftertwoweeks,onlythoserandomizedtorosiglitazone
in the no-tNRTI group experienced a signiﬁcant rise in
PPARγ and PGC-1 expression. At 48 weeks, PPARγ expres-
sion was increased in the no-tNRTI groups when compared
to tNRTI groups, but there was no diﬀerence between the
rosiglitazone and placebo arms [81].
The increase in the expression of adiponectin, PPARγ
(albeit limited), and that of PGC-1 are consistent with data
from type 2 diabetic patients treated with glitazones [82, 83].
Thereare,however,alsosomediﬀerencesinthesetwopatient
populations. In non-HIV patients, the expression of lipopro-
tein lipase (LPL) [82, 84] and adipocyte fatty acid binding
protein (aP2) [83] increased with glitazone treatment. The
expression of these genes remained unchanged in HAART-
treated patients [76].
Taken together, it seems plausible that thiazolidinedione
treatment had a functional eﬀect in lipoatrophic SAT by
increasing the production of adiponectin and decreasing IL-
6 expression. Both of these changes may have been involved
in the improvement of whole body insulin sensitivity. The
correlationbetweenthechangeinadiponectinconcentration
and the change in liver fat content implies a possibility for
adiponectin to have mediated this beneﬁcial eﬀect on liver
fat [76]. These functional changes in adipose tissue occurred
despite the lack of a signiﬁcant increase in fat mass. One
may also hypothesize that the blunted increase in PPARγ
expression, especially in patients receiving tNRTI therapy, as
well as the lack of an increase in LPL and aP2 expression
may all have contributed to the nonsigniﬁcant eﬀect on SAT
mass and to high-serum triglyceride concentration in these
patients.
4.4. Safety. Since in vitro and animal models, as well as
clinical studies clearly indicate that thiazolidinediones cor-
rect endothelial dysfunction, suppress chronic inﬂammatory
processes, reduce fatty streak formation, and enhance plaque
stabilization and regression [85], one would expect favorable
eﬀects on cardiovascular endpoints also in human studies.PPAR Research 9
Table 5: The eﬀects of thiazolidinediones on blood lipids in comparative studies with HIV infected, HAART-treated patients. HDL = high-
density lipoprotein, LDL = low-density lipoprotein, NS = nonsigniﬁcant, NR = not reported, CI = conﬁdence interval.
N Drug Duration Total cholesterol
(mmol/L)
HDL cholesterol
(mmol/L)
LDL cholesterol
(mmol/L)
Triglycerides
(mmol/L) Reference
30 Rosi versus
placebo 24 weeks
Rosi: +1.4,
∗P<. 01; pla: 0.0,
∗NS Δ rosi versus
pla NS
NS NR
NS At 12 weeks:
rosi: +3.0,
∗P<. 05; pla: NS
Sutinen et al. [55]
108 Rosi versus
placebo 48 weeks
Rosi: +0.9; pla: 0.0
Δ Rosi versus pla
P<. 001
NS
Rosi: +0.8; pla:
+0.4 Δ rosi versus
pla P = .04
Rosi: +1.5; pla:
+1.3 Δ rosi versus
pla P = .04
Carr et al. [56]
14
Pio versus
feno versus
pio + feno
versus
placebo
12 months NS
pio: +0.15, ∗NS;
pla: −0.20, ∗NS Δ
pio versus pla
P = .01
Pio: +1.7,
∗P = .07; pla:
−0.6, ∗NS
NS Gavrila et al. [65]
96 Rosi versus
placebo 2 4 w e e k s N SN SN SN S Cavalcanti et al.
[62]
28 Rosi versus
placebo 3m o n t h s
Rosi: +0.6; pla:
−0.4 Δ rosi versus
pla P = .007
NS
Rosi: +0.4; pla:
−0.4 Δ rosi versus
pla P = .01
NS Hadigan et al [57]
105
Rosi versus
metformin
versus rosi +
met versus
placebo
16 weeks
Rosi: +0.4,
∗P<. 05; all other
groups ∗NS
Rosi: −0.1,
∗P<. 001; all other
groups ∗NS Δ rosi
versus pla
P = .005; Δ rosi
versus rosi + met
P = .006
Rosi: +0.2,
∗P<. 05; all other
groups ∗NS Δ rosi
versus pla P = .048
NS Mulligan et al. [60]
130 Pio versus
placebo 48 weeks NS
Pio: +0.09; pla:
−0.08Δ pio versus
pla P = .005
NS NS Slama et al. [66]
37 Rosi versus
placebo 6 m o n t h s N SN RN RN S H a i d e r e t a l . [ 61]
39 Rosi versus
metformin 26 weeks
Rosi: +0.4, ∗NS;
met: −0.4,
∗P<. 05Δ rosi
versus met 0.8
(95% CI, 0.3 to
1.3)
Rosi: −0.15,
∗P<. 05; met:
+0.01, ∗NS Δ rosi
versus met 0.16
(95% CI, −0.35 to
−0.02)
Rosi: +0.2, ∗NS:
met: −0.4,
∗P<. 05Δ rosi
versus met 0.6
(95% CI, 0.2 to
1.1)
Rosi: +0.5,
∗ versus <0.05;
met: −0.6,
∗P<. 05Δ rosi
versus met 1.1
(95% CI, 0.4 to
2.6)
van Wijk et al. [58]
∗ denotes signiﬁcance within the study group compared to baseline value, Δ denotes comparison of the change between respective study groups.
In contrast, the meta analysis by Nissen and Wolski [86]
demonstrated that rosiglitazone as compared to the control
group signiﬁcantly increased (and not decreased) the odds
ratio for myocardial infarction (OR 1.43; 95% conﬁdence
interval [CI], 1.03 to 1.98; P = .03), and the odds ratio for
death from cardiovascular causes (OR 1.64; 95% CI, 0.98
to 2.74; P = .06). A more recent meta analysis conﬁrmed
the increased risk of myocardial infarction (RR 1.42; 95%
CI, 1.06 to 1.91; P = .02) and heart failure (RR 2.09;
95% CI, 1.52 to 2.88; P<. 001) with rosiglitazone, but
found no signiﬁcant increase in the risk of cardiovascular
mortality (RR 0.90; 95% CI, 0.63 to 1.26; P = .53) [87].
In contrast to ﬁndings with rosiglitazone, a meta-analysis
of pioglitazone found a decreased hazard ratio for death,
myocardial infarction, or stroke in patients receiving piogli-
tazone when compared to those receiving control therapy
(HR 0.82; 95% CI, 0.72 to 0.94; P = .005) [88]. However, the
hazardratioforseriousheartfailurewasincreasedinpatients
receiving pioglitazone versus the control patients (HR, 1.41;
95% CI, 1.14 to 1.76; P = .002) [88]. Whether these
deleterious eﬀects of glitazones on cardiovascular morbidity
would be diminished in patients receiving HAART, since
patients are usually younger, fewer have diabetes, and so
forth, or enhanced since HAART by itself increases risk for
myocardial infarction [4], remains to be studied. None of the
studies with HAART-treated patients using glitazones so far
have reported any signiﬁcant cardiovascular events.
In general, both rosiglitazone and pioglitazone were
well tolerated in all trials with HAART-treated patients.
However, the total number of HAART-treated patients
taking rosiglitazone and pioglitazone was only 281 and 82,
respectively, and none of the studies had followup beyond10 PPAR Research
one year. Furthermore, it is important to keep in mind that
due to exclusion criteria of these trials there are basically no
data on glitazones in HIV-infected patients with signiﬁcantly
increased liver function tests, high creatinine or triglyceride
concentrations, or low hemoglobin at baseline; all these
laboratory abnormalities are relatively common in HAART-
treated patients.
Regarding the known adverse eﬀect proﬁle of thiazo-
lidinediones in non-HIV infected patients, it was reassuring
that no cases of clinically signiﬁcant oedema, heart failure
or other cardiovascular events were reported. A decrease
in haemoglobin concentration is another known side eﬀect
with all glitazones, which is not explained by hemodilution
but possibly caused by mild suppressive eﬀect on bone mar-
row [89,90].ThismightbeofsigniﬁcanceinHAART-treated
patients, since both HIV per se and antiretroviral agents may
cause bone marrow suppression [91]. A statistically, but not
clinically signiﬁcant decrease in haemoglobin concentration
in the rosiglitazone arm was reported in one study, possibly
also reﬂecting good adherence to study medication [55]. A
single case with a decrease of haemoglobin concentration to
less than 110g/L was reported by Hadigan et al. [57]. Given
the concerns for severe liver toxicity induced by troglitazone
[92], liver function tests were carefully monitored in these
patients receiving polypharmacy. A single participant in a
pioglitazone trial discontinued the study due to an increase
in liver function tests >3 times upper limit of normal [65].
In contrast, three studies observed signiﬁcant decreases in
ALT concentrations either within the rosiglitazone arm or
when compared to placebo [55, 56, 58]. Adverse eﬀects on
blood lipids were already discussed earlier; two patients had
to discontinue rosiglitazone due to abnormal lipid values
[55, 62].
Harmful eﬀects of thiazolidinediones on bone meta-
bolism have recently been discussed in patients with type
2 diabetes. A recent analysis of the data from ﬁve glitazone
studies suggests that treatment with thiazolidinediones, pri-
marilyrosiglitazone,contributestoboneloss[93].Thiseﬀect
appears to be most prominent in postmenopausal women
[93]. The eﬀect on bone density may have special relevance
inHAART-treatedpatients,sincebothHIV-infectionassuch
and also antiretroviral therapy have been associated with
decreased bone mineral density [94]. None of the studies
using glitazones in HAART-treated patients have reported
eﬀects on bone density.
Potential for drug-drug interactions must always be
considered, when new medications are combined with
HAART. Most PIs and nonnucleoside reverse transcriptase
inhibitors (NNRTIs) are not only metabolized by CYP450
3A4butarealsoeitherinhibitors(PIs,ritonavirinparticular)
or inducers (NNRTIs) of the same enzyme and to lesser
extent of other isoforms of CYP450 [95]. Both rosiglitazone
and pioglitazone are predominantly metabolized by CYP450
2C8 (http://www.emea.europa.eu/). Rosiglitazone is not an
inducer of any tested human CYP450 isoforms, but has
shown moderate inhibition of 2C8 and low inhibition of 2C9
(http://www.emea.europa.eu/). There is no in vitro evidence
that pioglitazone would either inhibit or induce any of
the human CYP450 isoforms (http://www.emea.europa.eu/).
Interaction studies have not shown clinically signiﬁcant
interactions with rosiglitazone and substrates for CYP450
3A4. These interactions are not expected with pioglitazone
either (http://www.emea.europa.eu/).
There are currently very limited pharmacological data on
the concomitant use of thiazolidinediones and antiretroviral
drugs. Data from a limited number of patients by Oette
et al. suggest that rosiglitazone could be safely administered
together with either lopinavir or efavirenz [96]. Rosiglita-
zone,however,seemedtodecreasenevirapineconcentrations
and the authors recommend to monitor nevirapine serum
concentrations if these drugs are used concomitantly [96].
Serum PI concentrations were measured in one study with
rosiglitazone [55] and both PI and NNRTI concentrations
were measured in one pioglitazone study [66]. Neither study
observed any signiﬁcant change in the serum concentrations
of these antiretroviral drugs during the study period. None
of the studies reported any statistically signiﬁcant changes in
either HIV viral load or CD4 count within the glitazone arm
or between diﬀerent study arms. Nevertheless, six patients in
the pioglitazone arm versus two in the placebo arm (P = .1)
experienced viral breakthrough (>400 copies/ml) during a
pioglitazone trial [66]. It is not reported if these patients
were possibly taking nevirapine-based HAART (potential
interactionbetweennevirapineandrosiglitazone,seeabove).
Interestingly, in vitro both PPARγ (rosiglitazone, ciglitazone,
troglitazone) and PPARα (fenoﬁbrate) agonists have been
shown to inhibit HIV replication [97, 98].
5. Conclusions Regarding the Role of
Thiazolidinedionesinthe Treatment of
HAART-AssociatedMetabolicComplications
The available evidence does not support the use of thia-
zolidinediones for HAART-associated lipoatrophy although
they may have beneﬁcial eﬀects in subgroups of patients
such as those that do not receive concomitant tNRTI
therapy. The lack of eﬀect may at least partially be explained
by the decreased expression of PPARγ which has been
demonstrated not only in SAT of lipoatrophic HAART-
treatedpatients[41,42],butalsoinSATofhealthyvolunteers
after only a 2-week exposure to NRTIs including a thymidine
analog[40].However,ifathiazolidinedioneisusedforlipoa-
trophy, pioglitazone should perhaps be preferred because of
its more favorable eﬀects on serum lipids. Currently, the
best treatment option for HAART-associated lipoatrophy
is to replace tNRTIs by abacavir or tenofovir [27–29]o r
possibly to avoid use of NRTI altogether [99]. However, if
this causal treatment of lipoatrophy is not feasible due to
HIV resistance proﬁle or intolerance to other antiretroviral
agents, one may consider using uridine, which showed a
signiﬁcant increase in SAT in a small randomized, placebo-
controlled trial in lipoatrophic patients continuing tNRTI-
based HAART [100]. Pravastatin has also been shown to
increase SAT in HAART-treated patients in a single small
trial [101]. However, patients in this trial were not recruited
for lipoatrophy but hyperlipidemia and hence the eﬀect of
pravastatin in severely lipoatrophic patients remains to bePPAR Research 11
studied. Finally and most importantly, one should aim to
prevent lipoatrophy altogether by avoiding the use of tNRTIs
in the primary combinations of HAART as has recently been
suggested [102].
Glitazones, pioglitazone in particular, could however,
be used for the treatment of HAART-associated diabetes,
especially in patients with reduced amount of SAT. The
consistent data on the beneﬁcial eﬀects on insulin sensitivity
in HAART-treated patients support this, albeit none of these
studies recruited diabetic patients. The direct evidence of
the beneﬁts in diabetic HAART-treated patients is there-
fore still lacking. When using glitazones for diabetes in
HAART-treated patients, one must keep in mind the poten-
tial risk for heart failure associated with both glitazones and
increased risk for myocardial infarction with rosiglitazone.
Nevertheless, glitazones might be the preferred choice, since
metformin has been associated with further loss of SAT in
HAART-treated lipodystrophic patients [58, 103] and there
are no clinical data at all on other oral antidiabetic agents in
this patient population.
Finally, the potential therapeutic role of thiazolidine-
diones on liver-related morbidity in HAART-treated patients
should be evaluated. Patients who are infected with both
hepatitis C (HCV) and HIV seem to have higher liver
fat content than those having HCV monoinfection [104,
105] although some controversy exists [106]. Among HIV-
infected patients without chronic HCV infection, those
with lipodystrophy have increased liver fat content when
compared to age and BMI-matched HIV-negative subjects
orHAART-treatednonlipodystrophicpatients[48].It,there-
fore, appears that both prevalent coinfection with HCV and
HAART-induced metabolic complications put HIV-infected
patients at increased risk for liver steatosis.
In HIV-negative patients with nonalcohol hepatic steato-
sis, 6-month treatment with pioglitazone decreased liver fat
content, increased hepatic insulin sensitivity, and improved
histologic ﬁndings with regards to liver steatosis, ballooning
necrosis and inﬂammation [107]. In the study by Sutinen
et al., treatment with rosiglitazone decreased signiﬁcantly
liver fat content when compared to placebo in HAART-
treated patients, although patients were not recruited for
increased liver fat but for the presence of lipoatrophy [55].
Two additional trials reported signiﬁcant decreases in liver
function tests in the glitazone arms [56, 58]. Although
promising, it remains unknown whether glitazones would
also improve inﬂammatory changes in the liver in these
patients, since no biopsy data are so far available.
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